Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Ordinary Share Buy Back

15 May 2024 KR1 plc (“KR1” or the “Company”) Ordinary Share Buy Back The Directors note the significant discount to net asset value at which the shares currently trade and consider that the share price significantly undervalues the Company's portfolio and prospects. Accordingly, the Board of Directors (“Board”) has resolved to commence share repurchases in the market where it believes this to be in shareholders' interests, noting that share buybacks represent an attractive opportunity to increase the Company's investment exposure to its existing portfolio at reduced costs

Transaction in Own Shares

    15 May 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |14/05/2024|+---------------------------------------------------------------

Trading Statement

15 May 2024 Vesuvius plc - Trading Update   Vesuvius plc, a global leader in molten metal flow engineering and technology, announces the following update for the period 1 January to 30 April 2024. Summary · Performance in the period was in line with our expectations · We maintain our expectations for FY 2024 · Excluding India and EEMEA, Steel markets remained subdued at the beginning of the year, as anticipated · Foundry markets outside of India remained weak, particularly in EU27+UK and North Asia · We continue to perform robustly due to our differentiated

Photocure ASA: Results for the first quarter of 2024

Oslo, Norway, 15 May 2024 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 116.8 million in the first quarter of 2024 (Q1 2023: NOK 105.9 million), and EBITDA of NOK 7.9 million (NOK -1.2 million) following positive operational developments and cost control. The Company reiterates its business and financial guidance for 2024 with 40 to 70 new and upgraded Saphira™ blue light tower installations during the year, product revenue growth of 6% to 9% in constant currency, and positive EBITDA excluding business development expenses.“Photocure delivered positive

Inify Laboratories AB (publ) – summary of Annual General Meeting

Inify Laboratories AB, corp. no. 559345-4431, held its ordinary Shareholders’ Annual General Meeting at the company's premises on May 14, 2024. A total of 30,133,104 shares were represented at the Annual General Meeting, corresponding to 66.61% of the total number of shares and votes. The AGM resolved, with the required majority, on all matters in accordance with the Board of Directors's published proposal. Below is a summary of the main decisions made, for further details please refer to the notice available on the company's website.   Adoption of the accounts The Annual General

Orthex Corporation: Interim Report January–March 2024

Orthex Corporation, Stock exchange release, 15 May 2024 at 9.00 a.m. EESTMomentum builds: strong sales and improving profitability This release is a summary of Orthex Corporation’s Interim Report for the period January–March 2024. The complete report is attached to this release as a pdf-file. It is also available on Orthex’s website at https://investors.orthexgroup.com/.January–March 2024 · Invoiced sales amounted to EUR 22.9 million (21.2) · Net sales increased by 7.5% to EUR 22.0 million (20.5) · Adjusted EBITDA was EUR 3.8 million (3.4) · Adjusted EBITA was EUR 2.8

First Camp Group Interim report Q1 2024

First Camp, Scandinavia’s largest campsite chain, increased revenues in the first quarter of 2024 by nine percent vs same period in 2023, adjusted for effects from acquisitions (pro forma) and excluding the positive effect of an earlier Easter and seasonal opening.First quarter 2024 (same quarter last year in brackets) · Total revenue of SEK 104.1 million (81.3) · Pro forma revenue increased with 26% compared to Q1 2023 · Pro forma Adjusted EBITDA amounted to SEK -70.6 million (-76.3) · EBIT amounted to SEK -101.8 million (-114.9) · Cash flow from operating activities of

Implantica publishes Interim Report January – March 2024 (Q1)

RefluxStop™ on path to become standard of care for acid reflux treatmentSignificant events in the first quarter of 2024 · Submitted Premarket Approval (PMA) application for RefluxStop™ to U.S. FDA · First of three modules submitted · Next two modules to be submitted in estimated 2 three-month intervals · One time costs of EUR 2.5 million attributed to the FDA process including the Usability study during Q1 · Completed Human Factors Validation Study with 16 U.S. surgeons as part of the FDA PMA process · 20 U.S. foregut surgeons trained on the RefluxStop procedure

Minutes from the Annual General Meeting 2024 in Genetic Analysis AS

Oslo, Norway, May 15, 2024 - Genetic Analysis AS (the "Company", Ticker: GEAN) held its Annual General Meeting yesterday, May 14[th], at 15:00 hours (CET) on the Company's premises in Ulvenveien 80, Oslo. All items on the agenda were approved as proposed.The agenda for the meeting was as follows: 1. Election of a chairperson and a person to co-sign the minutes Chairperson Per Matsson was elected to chair the general meeting, and Jethro Holter was elected to co-sign the minutes with the chairperson. 2. Approval of the annual accounts and directors' report of Genetic Analysis AS for

MindArk Interim Report Q1 2024

MindArk PE AB (publ) ("MindArk", the "Company") hereby announces that the Company's interim report for Q1 2024 has been published. Comment from Acting CEO, Leif Evander Andersson: "Our financial results for the last quarter—both turnover and operating profit—did not match the figures from the same period last year. However, this discrepancy primarily stems from the first quarter of 2023 being exceptionally strong due to the launch of our 20th anniversary event, TWEN. In early 2024, MindArk has focused on advancing AI integration across the organization. This initiative is already

Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024

Key highlights Lundbeck’s revenue increased by 7% CER[1] (+5% DKK) to DKK 5,288 million in the first quarter of 2024, mainly driven by growth in the U.S. and Europe · United States: DKK 2,498 million (+9% CER; +7% DKK) · Europe: DKK 1,248 million (+9% CER; +6% DKK) · International Markets: DKK 1,481 million (+4% CER; -1% DKK) The revenue of Lundbeck’s strategic brands increased by 17% CER (+15% DKK), reaching DKK 3,759 million, representing 71% of total revenue · Brintellix[®]/Trintellix[®]: DKK 1,168 million (+11% CER; +8% DKK) · Rexulti[®]: DKK 1,115 million (+7%

Stora Enso Oyj: Notification of Change in Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act (13 May 2024)

STORA ENSO OYJ STOCK EXCHANGE RELEASE 15 May 2024 at 8:30 EESTStora Enso Oyj received a notification pursuant to chapter 9, section 5 of the Securities Market Act from BlackRock, Inc on 14 May 2024. On 13 May 2024, BlackRock's total holding, including holding through financial instruments, in Stora Enso’s shares fell below the 5 percent threshold. +----------------+--------------+-----------------------------+---------------+|  |% of shares |% of shares and voting rights|Total of both || |and voting |through financial instruments|in % (7.A + |

Integrum has been granted a registered trademark for OPRA® Implant System in the EU

Mölndal, Sweden – May 15, 2024 — Integrum (publ) (Nasdaq First North Growth Marketing: INTEG B) announces that the European Union Intellectual Property Office, EUIPO, has approved Integrum’s product registration application for the OPRA® Implant System.Until now, the OPRA® Implant system has been an unregistered mark without legal protection. As it is granted a registered trademark, Integrum now obtains unitary immaterial protection for the product in the entire territory of the EU. “We are very pleased to have obtained a registered trademark for OPRA®[ ]as it grants us legal

Salmon Evolution ASA: Notice of annual general meeting 2024

The annual general meeting of Salmon Evolution ASA will be held on Wednsday, 5 June 2023 at 10:00 (CEST).   The meeting will be conducted as a virtual meeting only, accessible online via Lumi AGM. All shareholders will be able to participate in the meeting, vote and ask questions from smartphones, tablets or desktop devices. For further information regarding online participation, please refer to the guide available at www.salmonevolution.no/investor/. No pre-registration is needed for attending online, but attendees must be loggedin before the meeting starts. Deadline for registration

Everfuel – Q1 2024: Focus on HySynergy 1 completion and execution of realigned strategy

Herning, Denmark, 15 May 2024 – Everfuel A/S today published its first quarter 2024 financial results. Key events Q1 2024: · HySynergy 1 start-up moved to second half 2024 due to failed commissioning tests of certain sub-systems provided by the supplier postponing internal Everfuel and supplier software validation  · LOI with undisclosed industrial offtaker of green hydrogen in Germany · Political agreement in Denmark for financing of the hydrogen pipeline infrastructure · Five trailers in operation, serving the Heinenoord bus station and upcoming bus depots in Germany ·

Techstep partners with Nordic mobile operator to advance product offerings

Techstep has recently entered into a partner agreement with a Nordic mobile operator to introduce Own software and managed services to their customers.   Under the agreement, Techstep will work closely with the mobile operator to adapt their services to an evolving market landscape. The collaboration, which represents a new market segment for Techstep, aims to optimise value chains and tailor solutions for a mutually beneficial product partnership.   "Earlier this year, Techstep launched a refocused commercial strategy, emphasising partner sales as a key channel for standardised and

Proposed climate action in the livestock sector could increase pandemic risks and other health threats

Animal agriculture negatively impacts the climate, public health and animal welfare, a group of experts argue in an article published today in Frontiers in Animal Science.  Improving one of these impacts risks making the other two worse, so authors of the recent study are urging policymakers to weigh the trade-offs between all of these major impacts. One Health approach towards food systems transformation reveals risks and benefits of different interventions. Credit: Frontiers in Animal Science. The figure

Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025)

Stockholm, Sweden, May 15, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today said that they expect Leqembi sales to total JPY 56.5 billion (approximately SEK 4 billion) for their fiscal year (FY) 2024 (April 2024 through March 2025). This would generate approximately SEK 360 M in net royalty to BioArctic. In Eisai’s FY2023 (April 2023 through March 2024), Leqembi sales reached JPY 4.3 billion, resulting in SEK 28.2 M in net royalty to BioArctic.Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-

Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing

Stockholm, Sweden, May 15, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. In the US, Leqembi is indicated for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as

Africa Energy Announces Corporate Update and First Quarter 2024 Results

VANCOUVER, BC, May 14, 2024 /CNW/ – Africa Energy Corp. (TSX Venture: AFE) (Nasdaq First North: AEC) (“Africa Energy” or the “Company”), an oil and gas exploration company, announces corporate update and financial and operating results for the three months ended March 31, 2024. FINANCIAL AND OPERATIONAL UPDATE The Company’s financial results for the three months ended March 31, 2024, have been negatively impacted by a US$23.1 million non-cash loss on revaluation of our investment in Block 11B/12B, which was due to changes in base assumptions for discount rates applied in the

Communiqué from the Annual General Meeting of Micro Systemation AB (publ)

At the Annual General Meeting of Micro Systemation AB (publ) (“MSAB”) on 14 May 2024, the following decisions were made.   Income statements and balance sheets The Annual General Meeting adopted the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet for the financial year 2023. Dividend The Annual General Meeting resolved, in accordance with the Board of Directors’ proposal, on an ordinary dividend of SEK 1.50 per share, to be paid through two partial payments. A first payment of SEK 1.00 per share with the record

Year-end Report April 2023 – March 2024

Good growth and record amount of launches January - March 2024 · Consolidated sales during the fourth quarter, January to March amounted to SEK 78.1 (60.3) million, an increase of 30%. Adjusted for non-recurring sales in the comparative quarter Q4 2022/23, the revenue amounted to 78.1 (53.5) MSEK, an increase of 46%. · Gross profit amounted to SEK 31.5 (28.1) million for the quarter, an increase of 11%. · EBIT amounted to SEK 8.4 (6.1) million, an increase of 38%. The operating margin was 11% (10%). · EBITDA margin was 14%. · Costs related to preparations for uplisting to

There are no items matching the current filter
There are no more items matching the current filter
Back to top